Regimen Reference Order - CUP - mFOLFOX-6

ARIA: CUP - [mFOLFOX-6]

Planned Course: Every 14 days until disease progression or unacceptable toxicity

Indication for Use: Carcinoma of Unknown Primary Site (CUP)

CVAD: Required (Ambulatory Pump)

Proceed with treatment if:

ANC equal to or greater than $1.5 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements				
Drug	Dose	CCMB Administration Guideline		
	No	ot Applicable		

Establish primary solution 500 mL of: D5W				
Drug	Dose	CCMB Administration Guideline		
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy		
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy		
oxaliplatin	85 mg/m ²	IV in D5W 500 mL over 2 hours *Nursing Alert: oxaliplatin and leucovorin may be infused over the same 2-hour period using a Y-site connector		
leucovorin	400 mg/m ²	IV in D5W 500 mL over 2 hours		
fluorouracil	400 mg/m ²	IV Push over 5 minutes		
fluorouracil	2400 mg/m ²	IV in D5W continuously over 46 hours by ambulatory infusion device		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'



ADULT CUP – mFOLFOX-6

REQUIRED MONITORING

All Cycles

• CBC, serum creatinine, electrolytes and liver enzymes as per Physician Orders

Recommended Support Medications			
Drug	Dose	CCMB Administration Guideline	
dexamethasone	8 mg	Orally once daily on Days 2 and 3	
prochlorperazine	10 mg	Orally every 6 hours as needed for nausea and vomiting	

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- Ensure patient has received a home chemotherapy spill kit and instructions for use
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- oxaliplatin causes cold intolerance and laryngopharyngeal dysesthesia
 - o no ice chips or cold drinks
- oxaliplatin may cause progressive, irreversible neuropathy
 - o dose modification may be required

